StrokeCasperNCT01904799
Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study
A study testing Cognitive Assessment test in people with Stroke, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions. The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke
- What is being tested?
- Cognitive Assessment test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 263 participants
- Where
- 1 siteFrance
- Study dates
- 2 Jan 2015to 29 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- For CVA patients
- patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ;
- aged > 18;
- absence of severe disorders of oral comprehension (BDAE aphasia severity score >2 for comprehension);
- whatever the severity of oral expression disorders;
- who have been given clear written and oral information, and after the doctor has verified their ability to understand the protocol.
Show all 9Show fewer
- For " Control " patients (to evaluate divergent validity)
- patients hospitalised in rehabilitation units or geriatrics taking part in this study;
- aged > 18.
Who cannot join
- For CVA patients
- patients who do not speak French;
- cognitive disorders known before the CVA;
- psychotic disorders known before the CVA;
- major visual disorders incompatible with reading, known before the CVA.
- For " Control " patients (to evaluate divergent validity)
Show all 10Show fewer
- patients who do not speak French;
- cognitive disorders known before the CVA;
- psychotic disorders known before the CVA;
- major visual disorders incompatible with reading, known before the CVA.
Trial locations and contacts
1 site in 1 country.
About this study
After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions.
The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions.
Read more
Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language.
The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :
- for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);
- the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.
- Conditions
- Stroke
- Being tested
- Cognitive Assessment test
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cognitive Assessment testOther
| Study group | Role | What they receive |
|---|---|---|
| Cognitive Assessment | Other | Not described Receives: Other: Cognitive Assessment test |
What is being measured
The primary outcome is the main question the study is designed to answer.
comprehensive assessment battery of higher functions
Measured: baseline
comprehensive assessment battery of higher functions
Measured: Evaluation at 3 ±1 days
comprehensive assessment battery of higher functions
Measured: Evaluation at 6 ± 2 weeks
test of visual memory
Measured: baseline
test of visual memory
Measured: Evaluation at 3 ±1 days
test of visual memory
Measured: Evaluation at 6 ± 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2013 (estimated)
- Study start2 Jan 2015
- Primary completion29 Mar 2019
- Study completion29 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 263 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01904799
- Sponsor's protocol ID
- Benaim PHRC N 2012
- Acronym
- Casper
- Status last verified
- Feb 2026
- First submitted
- 12 Jul 2013
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Benaim C, Wauquiez G, Perennou D, Piscicelli C, Lucas-Pineau B, Bonnin-Koang HY, Vuadens P, Binquet C, Bourredjem A, Devilliers H. Cognitive assessment scale for stroke patients (CASP): A multicentric validation study. Ann Phys Rehabil Med. 2022 May;65(3):101594. doi: 10.1016/j.rehab.2021.101594. Epub 2021 Nov 17.
PubMed 34687958
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study
- ClinicalTrials.gov ID
- NCT01904799
- Acronym / sponsor ID
- Casper / Benaim PHRC N 2012
- Conditions
- Stroke
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 263 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 2 Jan 2015 (actual)
- Primary completion
- 29 Mar 2019 (actual)
- Study completion
- 29 Mar 2019 (actual)
- First posted
- 22 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions.
The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions.
Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language.
The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :
- for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);
- the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cognitive Assessment | Other | Other: Cognitive Assessment test |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- For CVA patients
- patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ;
- aged > 18;
- absence of severe disorders of oral comprehension (BDAE aphasia severity score >2 for comprehension);
- whatever the severity of oral expression disorders;
Key exclusion criteria (10 listed)
- For CVA patients
- patients who do not speak French;
- cognitive disorders known before the CVA;
- psychotic disorders known before the CVA;
- major visual disorders incompatible with reading, known before the CVA.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cognitive Assessment test | Other | Cognitive Assessment |
Primary outcome
comprehensive assessment battery of higher functions
Time frame: baseline
comprehensive assessment battery of higher functions
Time frame: Evaluation at 3 ±1 days
comprehensive assessment battery of higher functions
Time frame: Evaluation at 6 ± 2 weeks
test of visual memory
Time frame: baseline
test of visual memory
Time frame: Evaluation at 3 ±1 days
test of visual memory
Time frame: Evaluation at 6 ± 2 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Results publication: PubMed 34687958Benaim C, Wauquiez G, Perennou D, Piscicelli C, Lucas-Pineau B, Bonnin-Koang HY, Vuadens P, Binquet C, Bourredjem A, Devilliers H. Cognitive assessment scale for stroke patients (CASP): A multicentric validation study. Ann Phys Rehabil Med. 2022 May;65(3):101594. doi: 10.1016/j.rehab.2021.101594. Epub 2021 Nov 17.
Related trials for Stroke
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Not yet recruiting
The Effects of an Augmented Reality-Based Mirror Therapy System in Patients With Stroke
Stroke
Recruiting
A Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke
Ischemic Stroke
RecruitingObservational study
Role of EEG in Differentiation Between Ischemic and Hemorrhagic Stroke
Acute Ischemic Stroke, Acute Haemorrhagic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cognitive Assessment test in people with Stroke, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
comprehensive assessment battery of higher functions (time frame: baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01904799, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.